Please wait

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13D/A 0001932843 XXXXXXXX LIVE 2 Common Stock, $0.001 par value 08/05/2025 false 0001130166 23254L801 Cyclacel Pharmaceuticals, Inc. 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 DAVID E. LAZAR 646-768-8417 44, Tower 100, The Towers Winston Churchill Panama City R1 07196 0001932843 N Lazar David E. PF N L3 0.00 0.00 0.00 0.00 0.00 N 0 IN Common Stock, $0.001 par value Cyclacel Pharmaceuticals, Inc. 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 The following constitutes Amendment No. 2 to the Schedule 13D filed by the undersigned ("Amendment No. 2). This Amendment No. 2 amends the Schedule 13D as specifically set forth herein. As a result of the transactions described herein, the filing of this Amendment No. 2 represents the final amendment to the Schedule 13D and constitutes an exit filing for the Reporting Person. Item 5(a) is hereby amended and restated as follows: The aggregate percentage of Shares owned by the Reporting Person is based upon 1,583,965 shares of Common Stock outstanding as of July 10, 2025, as reported in the Issuer's Registration Statement on Form S-1, which was filed with the Securities and Exchange Commission on July 30, 2025. As of the close of business on August 5, 2025, the Reporting Person did not beneficially own any Shares. Percentage: 0% Item 5(b) is hereby amended and restated as follows: 1. Sole power to vote or direct vote: 0 2. Shared power to vote or direct vote: 0 3. Sole power to dispose or direct the disposition: 0 4. Shared power to dispose or direct the disposition: 0 Item 5(c) is hereby amended and restated as follows: The transactions in the Shares by the Reporting Persons during the past sixty days are set forth in more detail in Exhibit 1 and are incorporated herein by reference. 1 - Transactions in the Securities Lazar David E. /s/ David E. Lazar David E. Lazar 08/08/2025